Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094319 | 0.92 | TRPV1 (0.48) | TRPV1ESR2ESR1ALDH1A1CYP3A4 | |
| SCHEMBL3105476 | 0.91 | ALDH1A1 (0.50) | TDP1L3MBTL1ALDH1A1MMP12FFAR1 | |
| SCHEMBL3093133 | 0.82 | HDAC1 (0.51) | TDP1ALDH1A1ALOX5 | |
| SCHEMBL30944447 | 0.79 | CYP2C19 (0.55) | L3MBTL1ESR2ESR1ALDH1A1CYP3A4 | |
| SCHEMBL13311578 | 0.74 | TRPV1 (0.64) | TRPV1TDP1L3MBTL1CYP19A1ALDH1A1 | |
| SCHEMBL8242742 | 0.74 | ALDH1A1 (0.57) | TDP1L3MBTL1ALDH1A1MMP12FFAR1 | |
| SCHEMBL11510565 | 0.73 | ESR2 (0.56) | ESR2ESR1ALDH1A1CYP3A4 | |
| SCHEMBL25332888 | 0.73 | CYP2C19 (0.69) | L3MBTL1ESR2ALDH1A1 | |
| SCHEMBL1202058 | 0.73 | CYP2C19 (0.69) | L3MBTL1ESR2ALDH1A1 | |
| SCHEMBL3291465 | 0.73 | CYP2C19 (0.69) | L3MBTL1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | claimed |
| EP-2227449-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-15 | — | — | EP | claimed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | claimed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| EP-2227449-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | HSD17B11, HSD17B7, CYP19A1 | TRPV1 3501/4885TDP1 4753/4885L3MBTL1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.